Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ: SRPT )

107.95 -1.51 (-1.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
FDA approves Sarepta's Elevidys for Duchenne muscular dystrophy patients with confirmed DMD gene mutation, aged 4+. Expanded label boosts revenue prospects for SRPT as payers and analysts show strong... 
Via Benzinga
Exposures Product Safety
Gold Down 1%; CarMax Shares Gain After Q1 Earnings
Via Benzinga
Sarepta Therapeutics Stock Soars on FDA Approval
Sarepta Therapeutics' expanded FDA approval for its DMD gene therapy, Elevidys, propels the company into a dominant position in the rare disease market. 
Via MarketBeat
Exposures Product Safety
Why Is Ascent Solar (ASTI) Stock Up 11% Today?
Ascent Solar stock is up on Friday with heavy trading of ASTI shares after the company announced a debt payoff to institutional investors. 
Via InvestorPlace
Why Is 36Kr (KRKR) Stock Up 17% Today?
36Kr stock is up Friday after the content creation company announced a partnership with SenseTime that brings heavy trading of KRKR shares. 
Via InvestorPlace
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts
Via Benzinga
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Stock Market Weekly Review: Nvidia, AI Chip Plays Hit Resistance
The Nasdaq and S&P 500 backed off highs. The Dow regained a key level. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Pre-Market Movers - June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging. 
Via InvestorPlace
Exposures Product Safety
Apple To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. 
Via Benzinga
Exposures Product Safety
Wall Street Looks Set For Modestly Lower Start Ahead Of Key Data, Tech Stocks Muted In Premarket: Analyst Says 'Bearish Sentiment Has Become Understandably Quiet'
Wall Street is on track for a lackluster open after the S&P 500’s back-to-back record performances in the first two sessions of the week. The major index futures were all uniformly lower in early... 
Via Benzinga
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
Via Investor's Business Daily
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
Via Investor's Business Daily
Exposures Product Safety
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside 
Via InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Sarepta Therapeutics Stock Is Rising Today
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400. 
Via Benzinga
Topics Stocks
Exposures US Equities
Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge. 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
Via InvestorPlace
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir
Jim Cramer likes Enbridge Inc. (NYSE: ENB), says Lazard, Inc. (NYSE: LAZ) is a good buy, and Advanced Drainage Systems, Inc. (NYSE: WMS) is an incredible infrastructure play. He also mentions Jacobs... 
Via Benzinga
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.